BRPI0715660B8 - anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal - Google Patents
anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonalInfo
- Publication number
- BRPI0715660B8 BRPI0715660B8 BRPI0715660A BRPI0715660A BRPI0715660B8 BR PI0715660 B8 BRPI0715660 B8 BR PI0715660B8 BR PI0715660 A BRPI0715660 A BR PI0715660A BR PI0715660 A BRPI0715660 A BR PI0715660A BR PI0715660 B8 BRPI0715660 B8 BR PI0715660B8
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- polypeptides
- human
- binding
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
- C12N5/12—Fused cells, e.g. hybridomas
- C12N5/16—Animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Abstract
anticorpo monoclonal ou fragmento de anticorpo, métodos para reduzir, bloquear, inibir, ou neutralizar inflamação, prurite e arranhadura em um mamífero, e, anticorpo isolado. são obtidas novas composições derivadas de sítios de ligação em antígeno de imunoglobulinas tendo afinidade por il-3 1. as composições exibem propriedades de ligação imunológicas de moléculas de anticorpo capazes de ligação especificamente em uma il-3 1 de humano. são obtidas regiões cdr derivadas de mesmos ou diferentes grupos de imunoglobulinas. também são obtidos polipeptídeos de cadeia única nos quais os domínios vh e vl estão ligados. as moléculas sfv podem incluir grupos de polipeptideo ancilares que podem ser bioativos, ou que proporcionam um sítio de ligação para outros grupos úteis. as composições são úteis em ensaios de ligação específicos, esquemas de purificação por afinidade, seleção de toxina ou droga, imagem, e agentes terapêuticos imunológicos ou genéticos para doenças inflamatórias. a invenção deste modo proporciona polipeptideos novos, os dnas codificadores daqueles polipeptídeos, cassetes de expressão compreendendo aqueles dnas, e métodos de indução da produção dos polipeptídeos. a invenção adicionalmente proporciona as seqtiências de aminoácidos das regiões variáveis dos anticorpos monoclonais e o uso destes anticorpos monoclonais ou fragmentos de anticorpo juntamente com uma molécula igg4 fc de humano.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US82440306P | 2006-09-01 | 2006-09-01 | |
US60/824403 | 2006-09-01 | ||
US89079207P | 2007-02-20 | 2007-02-20 | |
US60/890792 | 2007-02-20 | ||
PCT/US2007/077555 WO2008028192A2 (en) | 2006-09-01 | 2007-09-04 | Variable region sequences of il-31 monoclonal antibodies and methods of use |
Publications (3)
Publication Number | Publication Date |
---|---|
BRPI0715660A2 BRPI0715660A2 (pt) | 2013-07-02 |
BRPI0715660B1 BRPI0715660B1 (pt) | 2018-06-19 |
BRPI0715660B8 true BRPI0715660B8 (pt) | 2021-05-25 |
Family
ID=38752366
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0715660A BRPI0715660B8 (pt) | 2006-09-01 | 2007-09-04 | anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal |
Country Status (19)
Country | Link |
---|---|
US (6) | US8466262B2 (pt) |
EP (3) | EP2594586B1 (pt) |
JP (3) | JP2010502652A (pt) |
KR (1) | KR101501660B1 (pt) |
CN (2) | CN101522713A (pt) |
AU (1) | AU2007290145B2 (pt) |
BR (1) | BRPI0715660B8 (pt) |
CA (1) | CA2660175C (pt) |
CY (1) | CY1115939T1 (pt) |
DK (1) | DK2594586T3 (pt) |
ES (2) | ES2519375T3 (pt) |
HK (1) | HK1199047A1 (pt) |
IL (1) | IL196914A (pt) |
MX (1) | MX2009002242A (pt) |
PL (1) | PL2594586T3 (pt) |
PT (1) | PT2594586E (pt) |
RU (1) | RU2009111884A (pt) |
SI (1) | SI2594586T1 (pt) |
WO (1) | WO2008028192A2 (pt) |
Families Citing this family (54)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE401390T1 (de) * | 2002-01-18 | 2008-08-15 | Zymogenetics Inc | Zytokin (zcytor17-ligand) |
JP2008530132A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス, インコーポレイテッド | Il−31raアンタゴニストを用いて皮膚障害を治療する方法 |
EP1856539B1 (en) * | 2005-02-14 | 2015-10-21 | ZymoGenetics, Inc. | Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists |
MX2007013609A (es) | 2005-05-06 | 2008-01-24 | Zymogenetics Inc | Anticuerpos monoclonales de il-31 y meodos de uso. |
US20130216542A1 (en) | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
EP2594585A1 (en) | 2006-01-10 | 2013-05-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
CN101522713A (zh) | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体的可变区序列和使用方法 |
WO2008086505A2 (en) | 2007-01-10 | 2008-07-17 | Zymogenetics, Inc. | Methods of using il-31 to treat airway hyper-responsiveness and asthma |
US8470979B2 (en) | 2007-12-07 | 2013-06-25 | Zymogenetics, Inc. | Humanized antibody molecules specific for IL-31 |
CA2726512A1 (en) * | 2008-06-09 | 2009-12-17 | Novartis Ag | Antibodies against neisserial factor h binding protein |
US8790651B2 (en) | 2011-07-21 | 2014-07-29 | Zoetis Llc | Interleukin-31 monoclonal antibody |
CN103965363B (zh) * | 2013-02-06 | 2021-01-15 | 上海白泽生物科技有限公司 | 与pd-1和vegf高效结合的融合蛋白、其编码序列及用途 |
EA201592285A1 (ru) | 2013-05-30 | 2016-05-31 | Байоджен Ма Инк. | Антигенсвязывающие белки к рецептору онкостатина м |
JP6085746B2 (ja) * | 2014-08-11 | 2017-03-01 | 学校法人北里研究所 | 抗トロンボポエチン抗体の検出における検出感度の向上方法、免疫性血小板減少症の検出方法及びキット |
JP6302813B2 (ja) * | 2014-09-30 | 2018-03-28 | 日立ジョンソンコントロールズ空調株式会社 | スクロール圧縮機及びこれを用いた冷凍サイクル装置 |
KR102641898B1 (ko) | 2015-04-14 | 2024-02-27 | 추가이 세이야쿠 가부시키가이샤 | Il-31 안타고니스트를 유효 성분으로서 함유하는 아토피성 피부염의 예방용 및/또는 치료용 의약 조성물 |
RU2749512C2 (ru) * | 2015-04-14 | 2021-06-11 | Чугаи Сейяку Кабусики Кайся | Фармацевтическая композиция для профилактики и/или лечения атопического дерматита, включающая антагонист ил-31 в качестве активного ингредиента |
US11073670B2 (en) | 2016-08-12 | 2021-07-27 | Corning Optical Communications LLC | Device and method for sealing multiport splitters |
CN110248668B (zh) * | 2016-12-15 | 2023-05-30 | 杜克大学 | 用于消耗调节性b10细胞的抗体和方法以及与免疫检查点抑制剂的联用 |
WO2018156180A1 (en) | 2017-02-24 | 2018-08-30 | Kindred Biosciences, Inc. | Anti-il31 antibodies for veterinary use |
US10359577B2 (en) | 2017-06-28 | 2019-07-23 | Corning Research & Development Corporation | Multiports and optical connectors with rotationally discrete locking and keying features |
US11300746B2 (en) | 2017-06-28 | 2022-04-12 | Corning Research & Development Corporation | Fiber optic port module inserts, assemblies and methods of making the same |
US11668890B2 (en) | 2017-06-28 | 2023-06-06 | Corning Research & Development Corporation | Multiports and other devices having optical connection ports with securing features and methods of making the same |
HRP20221282T1 (hr) | 2017-06-28 | 2022-12-23 | Corning Research & Development Corporation | Višestruki priključci koji imaju spojne priključke sa ključevima i sigurnosne značajke |
US11187859B2 (en) | 2017-06-28 | 2021-11-30 | Corning Research & Development Corporation | Fiber optic connectors and methods of making the same |
WO2019086694A1 (en) * | 2017-11-06 | 2019-05-09 | Geert Mudde | Il31 antigen and vaccine |
EP3765500A2 (en) | 2018-03-16 | 2021-01-20 | Zoetis Services LLC | Interleukin-31 monoclonal antibodies for veterinary use |
MX2020009639A (es) | 2018-03-16 | 2021-01-08 | Zoetis Services Llc | Vacunas de peptídos contra interleucina-31. |
US10641967B1 (en) | 2018-11-16 | 2020-05-05 | Corning Research & Development Corporation | Multiport assemblies including a modular adapter support array |
US10768382B2 (en) | 2018-11-29 | 2020-09-08 | Corning Research & Development Corporation | Multiport assemblies including access apertures and a release tool |
CN109528663A (zh) * | 2018-12-20 | 2019-03-29 | 江西润泽药业有限公司 | 以ngr(no2)为靶向载体的抗癌药物冻干粉剂及其制备方法和应用 |
TW202106711A (zh) * | 2019-04-24 | 2021-02-16 | 美商健生生物科技公司 | 抗體調配物 |
US20220298255A1 (en) * | 2019-05-31 | 2022-09-22 | Seattle Children's Hospital D/B/A Seattle Children's Research Institute | E-cadherin activating antibodies and uses thereof |
US11294133B2 (en) | 2019-07-31 | 2022-04-05 | Corning Research & Development Corporation | Fiber optic networks using multiports and cable assemblies with cable-to-connector orientation |
MX2022002360A (es) * | 2019-08-29 | 2022-04-06 | Kindred Biosciences Inc | Anticuerpos de anti-il31 para uso veterinario. |
US11487073B2 (en) | 2019-09-30 | 2022-11-01 | Corning Research & Development Corporation | Cable input devices having an integrated locking feature and assemblies using the cable input devices |
EP3805827A1 (en) | 2019-10-07 | 2021-04-14 | Corning Research & Development Corporation | Fiber optic terminals and fiber optic networks having variable ratio couplers |
US11650388B2 (en) | 2019-11-14 | 2023-05-16 | Corning Research & Development Corporation | Fiber optic networks having a self-supporting optical terminal and methods of installing the optical terminal |
WO2021100794A1 (ja) | 2019-11-20 | 2021-05-27 | 中外製薬株式会社 | 抗体含有製剤 |
US11536921B2 (en) | 2020-02-11 | 2022-12-27 | Corning Research & Development Corporation | Fiber optic terminals having one or more loopback assemblies |
MX2023002482A (es) | 2020-09-01 | 2023-03-08 | Chugai Pharmaceutical Co Ltd | Composicion farmaceutica para prevencion y/o tratamiento de prurito por dialisis que comprende antagonista de interleucina 31 (il-31) como ingrediente activo. |
US11604320B2 (en) | 2020-09-30 | 2023-03-14 | Corning Research & Development Corporation | Connector assemblies for telecommunication enclosures |
US11686913B2 (en) | 2020-11-30 | 2023-06-27 | Corning Research & Development Corporation | Fiber optic cable assemblies and connector assemblies having a crimp ring and crimp body and methods of fabricating the same |
US11927810B2 (en) | 2020-11-30 | 2024-03-12 | Corning Research & Development Corporation | Fiber optic adapter assemblies including a conversion housing and a release member |
US11880076B2 (en) | 2020-11-30 | 2024-01-23 | Corning Research & Development Corporation | Fiber optic adapter assemblies including a conversion housing and a release housing |
EP4019547A1 (en) * | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Multispecific antibodies having specificity for il-4r and il-31 |
CN112480250B (zh) * | 2020-12-23 | 2022-03-15 | 上海交通大学 | 一种抗人骨桥蛋白的抗体及其应用 |
EP4019546A1 (en) * | 2020-12-23 | 2022-06-29 | Numab Therapeutics AG | Antibody variable domains that bind il-31 |
KR20230123981A (ko) * | 2020-12-23 | 2023-08-24 | 누맙 세러퓨틱스 아게 | Il-4r에 결합하는 항체 가변 도메인 |
US11947167B2 (en) | 2021-05-26 | 2024-04-02 | Corning Research & Development Corporation | Fiber optic terminals and tools and methods for adjusting a split ratio of a fiber optic terminal |
CN117209604B (zh) * | 2021-12-02 | 2024-03-22 | 北京东方百泰生物科技股份有限公司 | 一种抗tslp的单克隆抗体、其抗原结合片段及其应用 |
CN115505575B (zh) * | 2022-11-16 | 2023-03-24 | 中国科学院天津工业生物技术研究所 | 两株分泌犬il-31单克隆抗体的杂交瘤细胞株及其应用 |
CN117589031B (zh) * | 2024-01-19 | 2024-03-19 | 四川铁道职业学院 | 一种受电弓碳滑板磨损检测工具及其检测方法 |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
US4714681A (en) | 1981-07-01 | 1987-12-22 | The Board Of Reagents, The University Of Texas System Cancer Center | Quadroma cells and trioma cells and methods for the production of same |
US4474893A (en) | 1981-07-01 | 1984-10-02 | The University of Texas System Cancer Center | Recombinant monoclonal antibodies |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
IL71691A (en) | 1984-04-27 | 1991-04-15 | Yeda Res & Dev | Production of interferon-ypsilon |
WO1987001130A1 (en) | 1985-08-15 | 1987-02-26 | Stauffer Chemical Company | Tryptophan producing microorganism |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US5132405A (en) | 1987-05-21 | 1992-07-21 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5258498A (en) | 1987-05-21 | 1993-11-02 | Creative Biomolecules, Inc. | Polypeptide linkers for production of biosynthetic proteins |
US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
ZA894792B (en) | 1988-06-24 | 1991-04-24 | Dow Chemical Co | Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates |
BR8907507A (pt) | 1988-06-24 | 1991-06-11 | Dow Chemical Co | Quelante bifuncional macrociclico,seus complexos e seus conjugados com anticorpos |
US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
US4925648A (en) | 1988-07-29 | 1990-05-15 | Immunomedics, Inc. | Detection and treatment of infectious and inflammatory lesions |
US5601819A (en) | 1988-08-11 | 1997-02-11 | The General Hospital Corporation | Bispecific antibodies for selective immune regulation and for selective immune cell binding |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
GB2276169A (en) | 1990-07-05 | 1994-09-21 | Celltech Ltd | Antibodies specific for carcinoembryonic antigen |
ES2129029T5 (es) | 1990-10-05 | 2005-10-16 | Celldex Therapeutics, Inc. | Inmunoestimulacion dirigida con reactivos biespecificos. |
AU8727291A (en) | 1990-10-29 | 1992-06-11 | Cetus Oncology Corporation | Bispecific antibodies, method of production, and uses thereof |
JPH0578243A (ja) * | 1990-12-11 | 1993-03-30 | Shiseido Co Ltd | 鎮痒剤及び鎮痒組成物 |
WO1992010591A1 (en) | 1990-12-14 | 1992-06-25 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
DE69214709T2 (de) | 1991-04-26 | 1997-02-20 | Surface Active Ltd | Neue Antikörper und Verfahren zu ihrer Verwendung |
EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
ES2206447T3 (es) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
ES2202310T3 (es) | 1991-12-13 | 2004-04-01 | Xoma Corporation | Metodos y materiales para la preparacion de dominios variables de anticuerpos modificados y sus usos terapeuticos. |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
EP0627940B1 (en) | 1992-03-05 | 2003-05-07 | Board of Regents, The University of Texas System | Use of immunoconjugates for the diagnosis and/or therapy of vascularized tumors |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
CA2141602A1 (en) | 1992-08-26 | 1994-03-03 | Philip Leder | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
CA2196200A1 (en) | 1994-07-29 | 1996-02-15 | Michael Joseph Browne | Novel compounds |
EP1323346B1 (en) | 1995-01-17 | 2006-06-28 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
DE69731289D1 (de) | 1996-03-18 | 2004-11-25 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
PT1325115T (pt) | 2000-06-26 | 2016-09-28 | Zymogenetics Inc | Recetor de citocina zcytor17 |
EP2341060B1 (en) | 2000-12-12 | 2019-02-20 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
ATE401390T1 (de) * | 2002-01-18 | 2008-08-15 | Zymogenetics Inc | Zytokin (zcytor17-ligand) |
US7494804B2 (en) | 2002-01-18 | 2009-02-24 | Zymogenetics, Inc. | Polynucleotide encoding cytokine receptor zcytor17 multimer |
JP2006507839A (ja) * | 2002-11-27 | 2006-03-09 | ジーティーシー バイオセラピューティックス インコーポレイテッド | 乳中に安定して産生される改変抗体およびその製造方法 |
US8911726B2 (en) * | 2004-09-22 | 2014-12-16 | Kyowa Hakko Kirin Co., Ltd | Stabilized human Igg4 antibodies |
JP2008528039A (ja) | 2005-01-28 | 2008-07-31 | ザイモジェネティクス,インコーポレイティド | Il−31の均質調製物 |
JP2008530132A (ja) | 2005-02-14 | 2008-08-07 | ザイモジェネティクス, インコーポレイテッド | Il−31raアンタゴニストを用いて皮膚障害を治療する方法 |
EP1856539B1 (en) | 2005-02-14 | 2015-10-21 | ZymoGenetics, Inc. | Methods of predicting therapeutic response in atopic dermatitis to il-31 antagonists |
US20130216542A1 (en) * | 2005-05-06 | 2013-08-22 | Zymogenetics, Inc. | Variable region sequences of il-31 monoclonal antibodies and methods of use |
US8101183B2 (en) * | 2005-05-06 | 2012-01-24 | Zymogentics, Inc. | Variable region sequences of IL-31 monoclonal antibodies |
MX2007013609A (es) * | 2005-05-06 | 2008-01-24 | Zymogenetics Inc | Anticuerpos monoclonales de il-31 y meodos de uso. |
EP2594585A1 (en) * | 2006-01-10 | 2013-05-22 | Zymogenetics, Inc. | Methods of treating pain and inflammation in neuronal tissue using IL-31 antagonists |
CN101522713A (zh) * | 2006-09-01 | 2009-09-02 | 津莫吉尼蒂克斯公司 | Il-31单克隆抗体的可变区序列和使用方法 |
US8470979B2 (en) | 2007-12-07 | 2013-06-25 | Zymogenetics, Inc. | Humanized antibody molecules specific for IL-31 |
-
2007
- 2007-09-04 CN CNA2007800366660A patent/CN101522713A/zh active Pending
- 2007-09-04 EP EP13154481.9A patent/EP2594586B1/en active Active
- 2007-09-04 ES ES13154481.9T patent/ES2519375T3/es active Active
- 2007-09-04 DK DK13154481.9T patent/DK2594586T3/en active
- 2007-09-04 RU RU2009111884/10A patent/RU2009111884A/ru not_active Application Discontinuation
- 2007-09-04 US US12/439,079 patent/US8466262B2/en active Active
- 2007-09-04 MX MX2009002242A patent/MX2009002242A/es active IP Right Grant
- 2007-09-04 EP EP07814672A patent/EP2061811A2/en not_active Withdrawn
- 2007-09-04 AU AU2007290145A patent/AU2007290145B2/en active Active
- 2007-09-04 JP JP2009526951A patent/JP2010502652A/ja not_active Withdrawn
- 2007-09-04 PT PT131544819T patent/PT2594586E/pt unknown
- 2007-09-04 ES ES14165476.4T patent/ES2548714T3/es active Active
- 2007-09-04 PL PL13154481T patent/PL2594586T3/pl unknown
- 2007-09-04 CA CA2660175A patent/CA2660175C/en active Active
- 2007-09-04 SI SI200731534T patent/SI2594586T1/sl unknown
- 2007-09-04 BR BRPI0715660A patent/BRPI0715660B8/pt active IP Right Grant
- 2007-09-04 EP EP14165476.4A patent/EP2759549B1/en active Active
- 2007-09-04 KR KR1020097004994A patent/KR101501660B1/ko active IP Right Grant
- 2007-09-04 WO PCT/US2007/077555 patent/WO2008028192A2/en active Application Filing
- 2007-09-04 CN CN2012103636359A patent/CN103044550A/zh active Pending
-
2009
- 2009-02-05 IL IL196914A patent/IL196914A/en active IP Right Grant
-
2013
- 2013-05-15 US US13/895,008 patent/US9011858B2/en active Active
- 2013-12-26 JP JP2013269591A patent/JP6174481B2/ja active Active
-
2014
- 2014-11-24 CY CY20141100973T patent/CY1115939T1/el unknown
- 2014-12-17 HK HK14112678.8A patent/HK1199047A1/xx unknown
-
2015
- 2015-03-17 US US14/659,644 patent/US9624296B2/en active Active
-
2016
- 2016-01-08 JP JP2016002852A patent/JP2016106105A/ja active Pending
-
2017
- 2017-03-10 US US15/455,278 patent/US9878038B2/en active Active
- 2017-12-14 US US15/842,173 patent/US10434173B2/en active Active
-
2019
- 2019-08-22 US US16/548,584 patent/US20190374637A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0715660B8 (pt) | anticorpo isolado que se liga a il-31 humana, e, uso de um anticorpo monoclonal | |
Wu et al. | Molecular construction and optimization of anti-human IL-1α/β dual variable domain immunoglobulin (DVD-IgTM) molecules | |
BRPI0614040B8 (pt) | anticorpo isolado que se liga especificamente a b7rp1, polipeptídeo, composição farmacêutica, vetor de expressão, célula hospedeira, linhagem celular isolada e métodos para a detecção de b7rp1 em uma amostra biológica e de produção de um anticorpo ou polipeptídeo | |
BRPI0809042A8 (pt) | Proteína de ligação a cd154 isolada, seu uso, e composição | |
BRPI0607486A2 (pt) | anticorpo l243 humanizado, anticorpo biespecìfico ou fragmentos de ligação a antìgeno dos mesmos, composição farmacêutica, kit e uso dos referidos anticorpos | |
BRPI0819909B8 (pt) | anticorpo sintético humano ou humanizado isolado ou um fragmento funcional do mesmo, fragmento funcional e composição farmacêutica | |
US9908944B2 (en) | Antibodies that bind urokinase plasminogen activator | |
RU2007118670A (ru) | Ангиопоэтин-2-специфические связывающие агенты | |
CA2856141A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig scaffold for use in therapy | |
ES2608381T3 (es) | Anticuerpos anti-BMP-6 | |
HRP20210744T1 (hr) | Anti-c-met protutijela i njihovi konjugati protutijelo lijek za učinkovitu inhibiciju tumora | |
CA2856136A1 (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition | |
US20210347882A1 (en) | Antibodies to human resistin | |
ECSP055849A (es) | Anticuerpo ("11c7") anti-nogo a y su uso farmacéutico | |
JP2016531546A5 (pt) | ||
AU2014286131B2 (en) | Human anti-IFN-alpha antibodies | |
RU2009120536A (ru) | Рекомбинантные антитела против васкулярного эндотелиального фактора роста (vegf) | |
HRP20120975T1 (hr) | Terapeutska upotreba anti-cs1 antitijela | |
EP2209802B1 (en) | Resistin antagonists and their use | |
US20110071277A1 (en) | Resistin antagonists and their use | |
Grujic et al. | Impact of antibody subclass and disulfide isoform differences on the biological activity of CD200R and βklotho agonist antibodies | |
Bakherad et al. | Engineering an anti-granulocyte colony stimulating factor receptor nanobody for improved affinity | |
BR112017021830A2 (pt) | ?anticorpo monoclonal que neutraliza staphylococcus aureus, seu uso médico ou diagnóstico, uma preparação farmacêutica ou diagnóstica, moléculas de ácido nucleico que codificam o anticorpo e um método para produzir o anticorpo? | |
JP5587792B2 (ja) | 精製タグ又は不活性可変ドメインを具えるタンパク性結合分子 | |
CA3049967A1 (en) | Therapeutic anti-ige antibodies and methods and compositions thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] | ||
B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/09/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF |
|
B15V | Prolongation of time limit allowed |